PFENYSEPharmaceutical PreparationsFiscal year ends December 31
PFIZER INC
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026
$29.44−0.14 (-0.47%)
Close on Oct 19, 2026
- Market cap
- $167.78B
- P/E (TTM)
- 38.7
- Dividend yield
- 5.84%
PFIZER INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma [Member] | $61.20B | $62.40B | $58.24B | $99.83B | $79.56B | $40.72B | $38.01B | $37.56B | $35.53B | – | 97.8% | -1.9% |
| Innovative Health Segment [Member] | – | – | – | – | – | – | – | $33.43B | $31.42B | $29.20B | – | – |
| Essential Health Segment [Member] | – | – | – | – | – | – | – | $20.22B | $21.12B | $23.63B | – | – |
| Innovative Health and Essential Health [Member] | – | – | – | – | – | – | – | $53.65B | $52.55B | $52.82B | – | – |
| Upjohn [Member] | – | – | – | – | – | – | $10.23B | $12.48B | $13.45B | – | – | – |
| Pfizer CentreOne [Member] | – | – | – | – | $1.73B | $926.00M | $810.00M | – | – | – | – | – |
| PC1 [Member] | – | – | – | $1.34B | $1.73B | $926.00M | – | – | – | – | – | – |
| Business Innovation Segment [Member] | – | – | $1.31B | $1.34B | $1.73B | – | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $51.66B | $53.82B | $50.91B | $91.79B | – | – | – | – | – | – | 82.6% | -4.0% |
| Royalty [Member] | $1.65B | $1.42B | $1.06B | $845.00M | – | – | – | – | – | – | 2.6% | +16.0% |
| Pfizer CentreOne [Member] | $1.34B | $1.15B | $1.27B | $1.34B | – | – | – | – | – | – | 2.1% | +16.8% |
| Pfizer Ignite [Member] | $41.00M | $82.00M | $44.00M | $7.00M | – | – | – | – | – | – | 0.1% | -50.0% |
| Total Sterile Injectable Pharmaceuticals [Member] | – | – | – | – | $5.75B | $5.32B | $5.01B | $5.17B | – | – | – | – |
| Total Alliance revenues [Member] | – | – | – | – | $7.65B | $5.42B | $4.65B | $3.84B | – | – | – | – |
| Total Biosimilars [Member] | – | – | – | – | $2.34B | $1.53B | $911.00M | $769.00M | – | – | – | – |
| Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member] | – | $442.00M | – | – | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $37.08B | $38.69B | $28.15B | $43.32B | $29.75B | $21.46B | $20.33B | $20.12B | $26.03B | $26.37B | 59.2% | -4.2% |
| International Developed Markets [Member] | $16.19B | $16.06B | $20.91B | $40.53B | – | – | – | – | – | – | 25.9% | +0.8% |
| International Emerging Markets [Member] | $9.31B | $8.88B | $10.50B | $17.32B | – | – | – | – | – | – | 14.9% | +4.9% |
| Developed Rest of World [Member] | – | – | $7.76B | $15.78B | $12.51B | $4.04B | $4.02B | $4.09B | $6.61B | $6.73B | – | – |
| Emerging Markets [Member] | – | – | $12.00B | $20.10B | $20.70B | $8.37B | $8.83B | $8.62B | $11.40B | $10.42B | – | – |
| Developed Europe [Member] | – | – | $11.65B | $21.98B | $18.34B | $7.79B | $7.73B | $8.00B | $8.51B | $9.31B | – | – |
From the segment and revenue-disaggregation notes of Pfizer's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.